Posted in | News | Nanomedicine

Clinical Data on BIND Therapeutics’ BIND-014 Nanoparticle Drug Candidate Presented at AACR Meeting

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today that clinical data on its lead drug candidate, BIND-014, were presented at the American Association of Cancer Research (AACR) meeting.

The clinical data from a completed Phase 1 study demonstrate differentiating attributes of BIND-014 administered with a weekly dosing schedule which may enable increased dose intensity and enhanced therapeutic efficacy of BIND-014. In addition, data supporting the potential utility of PSMA as a target and marker for BIND-014 patient selection were presented.

BIND-014 is a targeted polymeric nanoparticle containing the cytotoxic agent docetaxel. In preclinical cancer models, BIND-014 was shown to increase accumulation of docetaxel at the site of disease which translated to marked improvements in antitumor activity and tolerability. BIND-014 is currently in two Phase 2 studies in non-small cell lung cancer and metastatic castrate resistant prostate cancer.

“These data demonstrated the unique attributes and potential benefits of BIND-014 as a valuable cancer therapy,” said Scott Minick, President and CEO of BIND. “We are highly encouraged that both the once weekly and once every three week dosing schedules of BIND-014 showed favorable safety and promising efficacy results, and we are evaluating both dosing schedules in our ongoing Phase 2 lung study to determine the optimal dose and schedule for BIND-014. In addition, we have generated data supportive of PSMA as a mechanistic target and potential biomarker for clinical patient selection.”

In a poster presentation entitled, “A phase 1 study of BIND-014, a PSMA-targeted nanoparticle containing docetaxel, administered to patients with refractory solid tumors on a weekly schedule,” BIND Therapeutics researchers presented Phase 1 data on safety, pharmacokinetics and preliminary efficacy of BIND-014 administered as a 60-minute infusion, once weekly for three weeks (Q1W), followed by one week of no treatment over a four-week cycle.

  • Greater dose intensity by approximately 50% was shown with Q1W dosing of BIND-014 as compared to once every three week dosing of BIND-014 described in a previous study.
  • Different tolerability profiles were demonstrated with BIND-014 dosed at Q3W and Q1W. The Q1W schedule demonstrated considerably less neutropenia than Q3W BIND-014, a major dose-limiting toxicity for docetaxel, even at the higher dose intensity.
  • Pharmacokinetics of BIND-014 were consistent with prolonged retention of BIND-014 particles in the vascular compartment and controlled release of docetaxel at the tumor.
  • Preliminary signals of antitumor activity were observed for BIND-014 administered on the Q1W schedule.
  • A Phase 2 clinical study in NSCLC examining both Q3W and Q1W dosing schedules is in progress.

In a poster presentation entitled, “Prostate-specific membrane antigen (PSMA) expression as a potential patient selection marker in patients with refractory solid tumors administered BIND-014, a PSMA-targeted nanoparticle containing docetaxel,” BIND Therapeutics researchers presented data from a retrospective analysis which demonstrated PSMA expression in patients responding to treatment with BIND-014 in the phase 1 clinical study.

  • Positive PSMA expression of moderate or high intensity was observed in patients who demonstrated a response to BIND-014 in the Phase 1 study.
  • Preferential expression of PSMA was observed on prostate cancer cells and vasculature of non-prostate solid tumors, but not in normal vasculature.
  • PSMA expression levels will be evaluated in the tumors of patients enrolled in Phase 2 clinical studies with BIND-014 to investigate the correlation between expression and efficacy as a potential basis for patient selection.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.